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Abstract
Background: Identifying biological pathways that vary across the age spectrum can provide insight into fundamental
mechanisms that impact disease and frailty in the elderly. Few methodological approaches offer the means to explore this
question on as broad a scale as gene expression profiling. Here, we have evaluated mRNA expression profiles as a function
of age in two populations; one consisting of 191 individuals with ages-at-death ranging from 65–100 years and with post-
mortem brain mRNA measurements of 13,216 genes and a second with 1240 individuals ages 15–94 and lymphocyte mRNA
estimates for 18,519 genes.
Principal Findings: Among negatively correlated transcripts, an enrichment of mitochondrial genes was evident in both
populations, providing a replication of previous studies indicating this as a common signature of aging. Sample differences
were prominent, the most significant being a decrease in expression of genes involved in translation in lymphocytes and an
increase in genes involved in transcription in brain, suggesting that apart from energy metabolism other basic cell processes
are affected by age but in a tissue-specific manner. In assessing genomic architecture, intron/exon sequence length ratios
were larger among negatively regulated genes in both samples, suggesting that a decrease in the expression of non-
compact genes may also be a general effect of aging. Variance in gene expression itself has been theorized to change with
age due to accumulation of somatic mutations and/or increasingly heterogeneous environmental exposures, but we found
no evidence for such a trend here.
Significance: Results affirm that deteriorating mitochondrial gene expression is a common theme in senescence, but also
highlight novel pathways and features of gene architecture that may be important for understanding the molecular
consequences of aging.
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Introduction
A decline in cell function with advancing age is a ubiquitous
characteristic of all organisms. In humans, the effects of aging
become manifest on a variety of levels that extend from an
accumulation of DNA mutations to lipid oxidation, protein
modification, cell loss, and ultimately death that is primarily due
to increased susceptibility to age-related diseases [1]. Apart from
overt changes, such as declining muscle strength, extensive
metabolic alterations also occur with aging, one of the most
prominent being impaired glucose tolerance [2]. Two central
evolutionary theories hypothesize that the detrimental effects of
aging are due to an accumulation of mutations, or antagonistic
pleiotropy, whereby genes with beneficial effects early in life
become deleterious with age [3]. These are not necessarily
exclusive, and there is at present relatively strong evidence for
both in studies of model organisms and in natural pop-
ulations [3,4].
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sequelae of aging on as broad a scale as possible. Few other
methodological approaches lend themselves as well to this as
mRNA expression profiling. There have been a handful of studies
that have attempted to catalogue how mRNA expression changes
with age, the largest of which have been performed in kidney [5]
and muscle samples [6]. An intriguing conclusion from the latter
study is that there may be a common set of genes that change
equivalently in different tissues. For example genes that make up
the mitochondrial electron transport chain appear to decrease with
age in different tissues, and this is supported in that decreases are
also evident in mice and flies [6]. Importantly however, these
studies remain relatively small in scale and few in number thus
meriting larger studies in additional populations and tissues.
The effects of aging are particularly pronounced in the human
brain where characteristic changes in morphology include a
reduction in both neuronal size and synaptic density [7,8]. On a
behavioral level, decreases in motor and cognitive function are
hallmarks of normal aging [9]. Dementia is the most prevalent
disorder of the human brain, affecting 20–25 million people
worldwide and representing a tremendous burden in terms of
years of suffering with disability [10]. To date, there has been only
one study, involving 30 individuals, on the effects of aging on gene
expression at a transcriptome-level in the normal human brain
[11]. There the authors described a number of pathways affected
by aging and also concluded that genes for which down-regulation
was evident had an over-representation of mutation in gene
promoters. A recent study examined the effects of gene
polymorphism on gene expression in a relatively large set of
human brain samples [12]. An attractive feature of that study was
that individuals, prior to death, were free of neurological disease.
Our primary focus in the present study has been to use the above
sample to investigate the question of whether general changes in
gene expression occur in the aging human brain. This has been
complemented with an analysis of lymphocyte mRNA expression
in order to explore for common molecular themes in different
tissues as well as to enable an assessment of a broader age range
than that typically available in post-mortem samples.
Results
We began by performing several validation steps towards the
initial goal of evaluating if age-related change in gene expression
could be detected in the human brain. First, evidence was sought
for systematic outlier effects among the 2,096,975 individual
expression level estimates. We identified all expression values that
were more than 3.4644 standard deviations from the mean
expression value for that particular transcript (see methods for an
explanation for choosing this threshold). With this, we expected to
see approximately 1,086 outliers by chance in the entire set
assuming normal distributions of the log10 transformed data.
There were 7,079 outliers identified in this way, and these were
eliminated from all further analyses. Second, the focus of the
original study was primarily upon brain cortex, with 5 subsets
being represented, 3 cortical, one group of 6 cerebellum samples
and an additional group of samples for which no specific region
could be assigned. We assessed whether these classifications
differed systematically with regards to transcript detection rates
and global expression levels using ANOVA (see methods). Across
the various brain region categories there were no significant
differences for any these covariates. Simple linear regression was
also performed for age-at-death and pmi versus global expression
level. For this, there was marginal evidence that age-at-death
correlated with global expression (P=0.080, r
2=0.016). For pmi
however, the trend was significant, but the direction of the curve
suggested that expression was increasing with increasing pmi
(P=0.0039. r
2=0.046). Of note, linear regression of the 2 global
expression covariates (see methods) and detection rate metrics (one
reflecting all 24,357 transcripts probed by the Illumina Human-
Refseq-8 chip and the other reflecting the 14,078 transcripts
detected in this brain sample) all showed strong correlation (r
2 in
excess of 0.5 for all 6 comparisons). Based upon all of the above
tests, we resolved to use the global average expression level that
includes all 14,078 transcripts as a primary metric of quality as a
covariate for initial analyses.
For the brain sample, we regressed age-at-death on transcript
levels one at a time for all 14,078 transcripts that had been
detected in 5 or more individuals in the original study. The results
of this are shown in Tables 1 and 2, where we document 54
transcripts that exhibited significant change after Bonferroni
correction for 14,078 tests. For purposes of illustration, regression
lines for the top 6 scoring genes (3 up-regulated and 3 down-
regulated) are also displayed in Figure 1. For this analysis, the most
significant finding was for the SVOP gene (encoding a synaptic
vesicle protein), and the single strongest effect in terms of variance
explained was for the TAC3 gene (encoding tachykinin 3). The
smallest number of individuals for which a significant correlation
with age was detected was 133 (also for the TAC3 gene). We noted
that 3 of the top scoring 54 genes were also present in a list of 532
putative ‘‘housekeeping’’ genes (see [13]), these being PIN1, GUK1,
and ARPC2. This proportion is not significantly different from
what would be expected by chance (3 vs. 51 compared to 532 vs.
6968). At this stage, we also scrutinized this list of 54 genes more
closely for the potential impact of covariates. For this, multiple
regression models were fitted as above, but for each transcript in
turn we also included terms for pmi, brain region, or gender. All
54 genes remained highly significant when any of these were
individually tested (not shown). Among the top 54 transcripts, all
were detectable in more than 100 individuals, reinforcing the
importance of power in analyses such as this. There were however
a few cases where a small number of observations gave rise to
apparently large effects. The gene that ranked as the 139
th most
significant finding (falling below the multiple test correction
threshold), ZIC3, had only 14 expression level observations and
an r
2=0.76 (P=2.6610
25). This highlighted the possibility that
genes with lower maximum expression levels might be changing to
a larger degree with age, but technologies with lower detection
thresholds and/or larger sample sizes would be required to identify
them.
We contrasted the individual transcript results of this analysis
with the first study to address the impact of aging on expression at
the transcriptome level [11]. In that study, 30 individuals were
included with an age range of 26–106. Our set was scrutinized for
the 148 genes previously highlighted to be associated with aging
(see specifically table 1 from [11]). Only one gene from our set that
survived strict multiple testing correction was also present in their
set, this being MRPL28. With a relaxed uncorrected significance
threshold in our set of 0.005, we found 26 overlapping genes. This
proportion is significant given that we observed 1,141 transcripts
in our set that were significant at the 0.005 threshold, suggesting
that some replication exists, albeit limited (26 vs. 122 compared to
1,141 vs. 12,937). In our set, the majority of significant genes
exhibited a decrease in expression with advancing age. An
intriguing aspect of this comparison was that among the 26
overlapping genes, there were 9 for which expression increased
with age in the original study, and for all 9 these were increased
with age in the present study. Due to the consistency in the
direction of the effects, this might be considered a stronger case for
Transcriptome Senescence
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class of stress response genes.
We explored an expanded list of genes that exceeded a relaxed
significance threshold (uncorrected P,0.05) for enrichment or
deficit based upon Gene Ontology (GO) terms and the Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways. The
entire set of genes was divided into two groups based upon
whether expression was increasing or decreasing with age. We
then searched for over- or under-represented terms and pathways
in each list of genes using the DAVID web application [14]. For
this we created a diminished non-redundant set of 13,216 base
genes from the total set of 14,078 by eliminating multiple
transcripts representing the same gene (see methods). The
enriched terms (Bonferroni corrected P,0.05) are shown in
Tables 3 and 4, excluding the ancestor terms that became
significant mainly by an overrepresented descendant in the GO
structure. A larger list of all overrepresented terms and pathways
with a less stringent threshold (uncorrected P,0.01) is shown in
Tables S1 and S2. In summarizing these results, the genes whose
products are involved in DNA-binding were the most significantly
overrepresented group among genes whose expression increases
with age (Table 4). Genes with products involved in the regulation
of DNA-dependent transcription and genes encoding proteins
located in or a subcomponent of the nucleus were also significantly
enriched. Among all genes negatively correlated with age, the most
significantly enriched groups included genes involved in nervous
system development, mitochondrial genes, and those whose
products are constituents of the cytoplasm (Table 3). We also
highlighted the degree of enrichment in terms of a fold change (the
number of genes that give rise to this number are shown in Tables
S1 and S2). Thus, in quantitative terms the most enriched genes
occurred in the set of negatively correlated transcripts, where
Table 1. Genes whose expression decreases with age in the human brain.
Symbol Description Chr.Pos P value
a R
2b
SVOP SV2 related protein homolog (rat) 12q 4.3(10
29) 0.14
HBQ1 hemoglobin, theta 1 16p 8.6(10
28) 0.13
MRPL28 mitochondrial ribosomal protein L28 16p 1.0(10
27) 0.14
TAC3 tachykinin 3 (neuromedin K, neurokinin beta) 12q 1.0(10
27) 0.18
C6orf154 chromosome 6 open reading frame 154 6p 1.5(10
27) 0.13
SLC25A6 solute carrier family 25, member A6 Xp/Yp 1.9(10
27) 0.14
ST3GAL2 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 16q 2.2(10
27) 0.15
PIN1 peptidylprolyl cis/trans isomerase, NIMA-interacting 1 19p 3.2(10
27) 0.13
ARPC2 actin related protein 2/3 complex, subunit 2, 34 kDa 2q 3.2(10
27) 0.14
KCNF1 potassium voltage-gated channel, subfamily F, member 1 2p 4.1(10
27) 0.12
GSS glutathione synthetase 20q 4.3(10
27) 0.11
LOC255849 hypothetical LOC255849 4.5(10
27) 0.12
HMGB3 high-mobility group box 3 Xq 4.8(10
27) 0.13
TMEM121 transmembrane protein 121 14q 6.1(10
27) 0.14
CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 1p 6.4(10
27) 0.12
OLFM1 olfactomedin 1 9q 7.4(10
27) 0.13
KCNIP1 Kv channel interacting protein 1 5q 9.2(10
27) 0.12
FABP3 fatty acid binding protein 3 1p 1.1(10
26) 0.08
GUK1 guanylate kinase 1 1q 1.2(10
26) 0.13
COPS7A COP9 constitutive photomorphogenic homolog subunit 7A (Arabidopsis) 12p 1.3(10
26) 0.07
VIP vasoactive intestinal peptide 6q 1.4(10
26) 0.11
PQLC1 PQ loop repeat containing 1 18q 1.6(10
26) 0.13
FLJ34048 hypothetical transcript 1.6(10
26) 0.12
CYP46A1 cytochrome P450, family 46, subfamily A, polypeptide 1 14q 2.0(10
26) 0.11
ATG7 ATG7 autophagy related 7 homolog (S. cerevisiae) 3p 2.1(10
26) 0.11
CXCL14 chemokine (C-X-C motif) ligand 14 5q 2.3(10
26) 0.13
NXPH1 neurexophilin 1 7p 2.6(10
26) 0.11
C17orf76 chromosome 17 open reading frame 76 2.7(10
26) 0.17
NPM3 nucleophosmin/nucleoplasmin, 3 10q 3.1(10
26) 0.08
LHX6 LIM homeobox 6 9q 3.2(10
26) 0.07
FRMPD2 FERM and PDZ domain containing 2 10q 3.4(10
26) 0.07
HSD11B1L hydroxysteroid (11-beta) dehydrogenase 1-like 19p 3.5(10
26) 0.12
SMAD3 SMAD family member 3 15q 3.5(10
26) 0.09
aP-value with the null hypothesis b1=0 in linear regression model Y=b0+b1x1+b2x2+e, where Y is transcript expression, x1 age-at-death, x2 global expression, and e
random error.
bCoefficient of determination of linear regression model Y=b0+b1x1+e, where each variable is as described above.
doi:10.1371/journal.pone.0003024.t001
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were enriched more than 3 fold (Table 3). In contrast, although
highly significant in some cases, genes whose expression is
increasing with age are enriched a maximum of 1.80 fold
(Table 4). As a comparison, the probabilities for the enriched
terms to be underrepresented by chance within the opposite group
Table 2. Genes whose expression increases with age in the human brain.
Symbol Description Chr.Pos P value
a R
2b
ELF2 E74-like factor 2 (ets domain transcription factor) 4q 5.3(10
29) 0.16
C1orf162 chromosome 1 open reading frame 162 1p 6.0(10
29) 0.13
LRCH4 leucine-rich repeats and calponin homology (CH) domain containing 4 7q 2.9(10
28) 0.09
MTUS1 mitochondrial tumor suppressor 1 8p 6.8(10
28) 0.12
RUFY1 RUN and FYVE domain containing 1 5q 7.0(10
28) 0.10
RDH5 retinol dehydrogenase 5 (11-cis/9-cis) 12q 1.4(10
27) 0.06
TYK2 tyrosine kinase 2 19p 1.8(10
27) 0.10
CLK1 CDC-like kinase 1 2q 2.1(10
27) 0.14
TXNIP thioredoxin interacting protein 1q 2.1(10
27) 0.10
SLC16A9 solute carrier family 16 (monocarboxylic acid transporters), member 9 10q 4.8(10
27) 0.06
ADORA3 adenosine A3 receptor 1p 5.1(10
27) 0.10
UCKL1 uridine-cytidine kinase 1-like 1 20q 7.4(10
27) 0.11
CTDSP2 nuclear LIM interactor-interacting factor 2 12q 1.1(10
26) 0.05
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 6p 1.2(10
26) 0.09
PATL1 protein associated with topoisomerase II homolog 1 (yeast) 11q 1.4(10
26) 0.12
GDPD3 glycerophosphodiester phosphodiesterase domain containing 3 16p 1.4(10
26) 0.07
BHLHB3 basic helix-loop-helix domain containing, class B, 3 12p 1.7(10
26) 0.07
RNASE4 ribonuclease, RNase A family, 4 14q 1.9(10
26) 0.06
PLEKHM1 pleckstrin homology domain containing, family M (with RUN domain) member 1 17q 2.5(10
26) 0.04
FAM46A family with sequence similarity 46, member A 6q 3.4(10
26) 0.06
CALCOCO1 calcium binding and coiled-coil domain 1 12q 3.5(10
26) 0.09
aP-value with the null hypothesis b1=0 in linear regression model Y=b0+b1x1+b2x2+e, where Y is transcript expression, x1 age-at-death, x2 global expression, and e
random error.
bCoefficient of determination of linear regression model Y=b0+b1x1+e, where each variable is as described above.
doi:10.1371/journal.pone.0003024.t002
Figure 1. Scatter plots and fitted linear regression lines of the most significantly associated down-regulated (a–c) and up-regulated
(d–f) genes with age-at-death in brain samples.
doi:10.1371/journal.pone.0003024.g001
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For example, from Table 4, we show that the term ‘‘nucleus’’
which is significantly enriched in the set of genes that are
increasing with age is also in deficit in the set of genes that are
decreasing with age.
We extended the above analytical scheme to a second sample
consisting of 1240 individuals with lymphocyte mRNA measures
for 19,648 transcripts representing 18,519 genes. We note that a
rigorous standardization procedure had been applied to this set
previously [15] and we thus elected not to perform any additional
transformations, nor to include any additional covariates (see
methods). Linear regression was performed as above on all 19,648
transcripts versus age for this sample. Given its size, and compared
to the brain sample, there were many more transcripts that
exceeded a strict Bonferroni significance threshold, and we chose
to present only the top 50 (25 negatively and 25 positively
correlated with age) which are shown in Tables 5 and 6, arbitrarily
truncated from a total of 1080 (612 negative and 468 positive).
The top 3 scoring negatively regulated genes and top 3 scoring
positively regulated genes are shown in Figure 2. The most
significant finding in this set was for the LRRN3 (encoding a
membrane protein with unknown function), and this was also the
gene upon which age exhibited the largest effect (28% variance
explained). Interestingly, the second largest effect observed in this
set was 14% variance explained, representing in our view an
anomalous drop from the top ranking gene. As was done for the
brain sample, we again divided this list into up- and down-
regulated genes and performed term/pathway based analyses. An
arbitrary significance level of 0.01 was chosen from the linear
regression results to establish these 2 lists (this differed from the
Table 3. Terms in the Gene Ontology and KEGG pathway databases over-represented among genes that decreased expression
with advancing age in the human brain (1,450 genes in total 13,216).
Category Term P value
a Bonferroni Fold
b Increasing group
c
Fold
b P value
d
GO Bio.Process nervous system development 7.8(10
29) 3.8(10
25) 1.73 0.76 6.7(10
23)
synaptic transmission 7.4(10
27) 3.5(10
23) 2.07 0.28 3.1(10
27)
oxidative phosphorylation 1.4(10
26) 6.7(10
23) 2.73 0.15 5.3(10
25)
GO Cell.Component cytoplasmic part 9.0(10
211) 7.2(10
28) 1.29 0.76 4.2(10
211)
mitochondrion 1.5(10
210) 1.2(10
27) 1.65 0.54 7.7(10
210)
neuron projection 2.3(10
210) 1.8(10
27) 3.41 0.40 1.0(10
22)
synapse 1.8(10
29) 1.4(10
26) 2.55 0.42 6.4(10
24)
mitochondrial membrane part 8.7(10
29) 6.9(10
26) 2.95 0.14 1.8(10
25)
mitochondrial inner membrane 3.1(10
28) 2.5(10
25) 2.11 0.45 5.4(10
25)
mitochondrial respiratory chain 4.9(10
26) 3.9(10
23) 2.99 0.11 4.3(10
24)
dendrite 5.2(10
26) 4.2(10
23) 3.60 0.17 1.1(10
22)
GO Mol.Function hydrogen ion transmembrane transporter activity 1.8(10
26) 4.7(10
23) 2.70 0.58 5.1(10
22)
KEGG Pathway Oxidative phosphorylation 1.9(10
29) 3.8(10
27) 2.66 0.25 1.4(10
24)
aEASE-score, P-value of a modified Fisher’s exact test for overrepresentation [35].
bFold enrichment in each gene group compared to the base set.
cGene group with
expression that increases with advancing age-at-death (same genes used in Table 4, 1943 genes).
dHypergeometric test for underrepresentation using annotated genes
from a total set of 13,216 genes as base population [36].
doi:10.1371/journal.pone.0003024.t003
Table 4. Terms in the Gene Ontology and KEGG pathway databases over-represented among genes that increased expression
with advancing age in the human brain (1,943 genes in total 13,216).
Category Term P value
a Bonferroni Fold
b Decreasing group
c
Fold
b P value
d
GO Bio.Process regulation of transcription, DNA-dependent 2.1(10
213) 1.0(10
29) 1.43 0.56 6.1(10
213)
chromosome organization and biogenesis 1.4(10
27) 6.8(10
24) 1.80 0.53 1.4(10
23)
DNA packaging 4.7(10
26) 2.2(10
22) 1.78 0.49 1.9(10
23)
DNA metabolic process 6.4(10
26) 3.0(10
22) 1.45 0.59 7.6(10
25)
GO Cel.Component nucleus 1.2(10
213) 9.6(10
211) 1.26 0.75 3.7(10
211)
GO Mol.Function DNA binding 6.8(10
214) 1.7(10
210) 1.44 0.52 1.1(10
214)
zinc ion binding 1.7(10
211) 4.3(10
28) 1.39 0.64 6.3(10
29)
transcription regulator activity 1.1(10
26) 2.7(10
23) 1.38 0.65 1.8(10
25)
aEASE-score, P-value of a modified Fisher’s exact test for overrepresentation [35].
bFold enrichment in each gene group compared to the base set.
cGene group with
expression that decreases with advancing age-at-death (same genes used in Table 3, 1450 genes).
dHypergeometric test for underrepresentation using annotated
genes from a total set of 13,216 genes as base population [36].
doi:10.1371/journal.pone.0003024.t004
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number of genes exceeding significance in lymphocytes and a 2000
gene limit set by the DAVID web tool). The total set of 19,648
transcripts for which regression was performed, was reduced to
13,231 for which annotations could be obtained towards analysis
using the DAVID web application. The results of this are shown in
Tables 7 and 8 where Bonferroni corrected (P,0.05) enriched
terms and pathways are documented. As was done for the brain
sample, an expanded list of enriched terms and pathways
according to relaxed uncorrected significance threshold of
P,0.01 is shown in Tables S3 and S4. The main highlight in
our view is the highly significant enrichment of mitochondrial
genes in the negatively regulated group (Table 7), providing a
replication of what was seen in the brain. In general, the
magnitude of the fold-change in term/pathway enrichment was
larger in the set of negatively regulated genes, also in agreement
with what was seen in brain.
Based upon the identified lists of age-related genes for both
brain and lymphocyte samples, we also explored for differences in
basic genomic architecture. Our guide for this was a detailed
analysis recently presented on characteristics of housekeeping
genes [13]. The results of this analysis are presented in Tables 9
and 10, where we document the differences between the up and
down-regulated sets in comparison with the characteristics of the
non-regulated genes. In summarizing these results, while we found
some striking differences, for example with coding sequence length
in brain, we note that this was not replicated in lymphocytes.
Instead we highlight a single category that does appear to be
replicating, namely the ratio of average intron to average exon
sequence length. We used second-order factorial ANOVA models
to perform combined analyses for all variables. For this, the
intron/exon sequence ratio is highly significant (F2,24158=41.57,
P=9.5610
219) with no evidence of interaction between the two
sets (P=0.69). This can be taken in context with the same analysis
for coding sequence length, where the tissue by group (group
defined by up, down, or non-regulated genes) interaction term was
highly significant (P,0.0001). For all other combined analyses, the
main group effect was either non-significant or the interaction
term was highly significant (P,0.0001).
Finally, we used these two samples to pursue the question of
whether variance in gene expression itself changes with age. Our
hypothesis was that variance might increase with age as a
consequence of accumulating somatic mutation [11] and/or
increasingly heterogeneous environmental exposures. For the brain
sample, an F-test for equality of variances was conducted on all
14,078transcriptsbydividingthesampleintwo groupsaccordingto
the median age. We observed only 10 genes that exceeded a strict
multiple test correction threshold and in each case there was
evidence that the distributions of these genes deviated from
normality. There was no overlap in this set for the highest scoring
candidates with genes found to change with age in the linear
regression analyses. There were 6 cases where an age-related gene
Table 5. Genes whose expression decreases with age in human lymphocytes.
Symbol Description Chr.Pos P value
a R
2
LRRN3 leucine rich repeat neuronal 3 7q 5.1(10
294) 0.29
FCGBP Fc fragment of IgG binding protein 19q 7.5(10
244) 0.14
FBLN2 fibulin 2 3p 8.1(10
244) 0.14
NRCAM neuronal cell adhesion molecule 7q 3.3(10
243) 0.14
ITM2C integral membrane protein 2C 2q 1.8(10
239) 0.13
PDE9A phosphodiesterase 9A 21q 4.9(10
237) 0.12
ZNF154 zinc finger protein 154 19q 5.3(10
236) 0.12
ZSCAN18 zinc finger and SCAN domain containing 18 19q 4.7(10
235) 0.12
SATB1 SATB homeobox 1 3p 9.8(10
235) 0.11
FLNB filamin B, beta (actin binding protein 278) 3p 1.1(10
234) 0.11
FAM134B family with sequence similarity 134, member B 5p 3.1(10
234) 0.11
SCD stearoyl-CoA desaturase (delta-9-desaturase) 10q 8.8(10
234) 0.11
SREBF1 sterol regulatory element binding transcription factor 1 17p 4.5(10
233) 0.11
CCR7 chemokine (C-C motif) receptor 7 17q 6.3(10
233) 0.11
PHGDH phosphoglycerate dehydrogenase 1p 1.1(10
232) 0.11
LEF1 lymphoid enhancer-binding factor 1 4q 5.3(10
232) 0.11
NPM3 nucleophosmin/nucleoplasmin, 3 10q 9.8(10
232) 0.11
OXNAD1 oxidoreductase NAD-binding domain containing 1 3p 2.1(10
231) 0.10
TNNT3 troponin T type 3 (skeletal, fast) 11p 3.4(10
230) 0.10
PLEKHG4 16q 5.8(10
230) 0.10
MGC9913 hypothetical protein MGC9913 1.5(10
229) 0.10
SLC7A6 solute carrier family 7 (cationic amino acid transporter, y+ system), member 6 16q 4.4(10
229) 0.10
CD27 CD27 molecule 12p 6.1(10
229) 0.10
AEBP1 AE binding protein 1 7p 1.0(10
228) 0.10
MGC29506 hypothetical protein MGC29506 5q 1.2(10
228) 0.09
aP-value with the null hypothesis b1=0 in linear regression model Y=b0+b1x1+e, where Y is transcript expression, x1 age, and e random error.
doi:10.1371/journal.pone.0003024.t005
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Symbol Description Chr.Pos P value
a R
2
IGFBP3 insulin-like growth factor binding protein 3 7p 1.7(10
270) 0.22
SYT11 synaptotagmin XI 1q 7.4(10
260) 0.19
GZMH granzyme H (cathepsin G-like 2, protein h-CCPX) 14q 2.0(10
248) 0.16
JAKMIP1 janus kinase and microtubule interacting protein 1 4p 5.4(10
245) 0.15
RCAN2 regulator of calcineurin 2 6p 1.5(10
243) 0.14
CRIP1 cysteine-rich protein 1 (intestinal) 14q 1.9(10
239) 0.13
PATL2 protein associated with topoisomerase II homolog 2 (yeast) 1.2(10
238) 0.13
MSC musculin (activated B-cell factor-1) 8q 5.9(10
232) 0.11
GDPD5 glycerophosphodiester phosphodiesterase domain containing 5 11q 3.1(10
230) 0.10
APOBEC3H apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3H 22q 2.3(10
229) 0.10
CCL5 chemokine (C-C motif) ligand 5 17q 7.1(10
229) 0.10
GFI1 growth factor independent 1 transcription repressor 1p 2.4(10
228) 0.09
MANEAL mannosidase, endo-alpha-like 1p 2.9(10
228) 0.09
KIF21A kinesin family member 21A 12q 3.1(10
227) 0.09
GPR137B G protein-coupled receptor 137B 1q 5.4(10
227) 0.09
PDGFRB platelet-derived growth factor receptor, beta polypeptide 5q 3.7(10
226) 0.09
PCBP4 poly(rC) binding protein 4 3p 8.1(10
226) 0.09
B3GAT1 beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P) 11q 1.1(10
225) 0.08
LLGL2 lethal giant larvae homolog 2 (Drosophila) 17q 4.7(10
225) 0.08
LAG3 lymphocyte-activation gene 3 12p 5.1(10
225) 0.08
PPP2R2B beta isoform of regulatory subunit B55, protein phosphatase 2 isoform b 5q 1.5(10
224) 0.08
hypothetical gene supported by BC040060 9.1(10
224) 0.08
PRSS23 protease, serine, 23 11q 1.5(10
223) 0.08
B4GALT5 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 5 20q 1.9(10
222) 0.07
MXRA7 matrix-remodelling associated 7 17q 3.0(10
222) 0.07
aP-value with the null hypothesis b1=0 in linear regression model Y=b0+b1x1+e, where Y is transcript expression, x1 age, and e random error.
doi:10.1371/journal.pone.0003024.t006
Figure 2. Scatter plots and fitted linear regression lines of the most significantly associated down-regulated (a–c) and up-regulated
(d–f) genes with age in lymphocyte samples.
doi:10.1371/journal.pone.0003024.g002
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was not significantly different than what could be found in the entire
set (not shown). For the lymphocyte set, we took a slightly different
approach due to its size and rather than dividing the sample at the
median chose to examine decile bins and applied a Levene’s robust
variance test to explore for differences across age groups. There was
again no strong evidence that variance differed across these
groupings, the most significant finding being for the NLP gene
(P=2.3610
26), and with only 2 genes in total attaining significance
after multiple test correction. As a final closing note, we enumerated
the number of statistical tests used in this study in its entirety,
arriving at an approximate number of 110,000. This may be used as
a reference for any of the un-corrected P-values that are presented.
Discussion
We consider the most important finding in this study to be that
expression levels of genes involved in mitochondrial processes are
decreasing with age, as originally proposed by Zahn et al. and also
supported by Miller et al. [6,16]. In the former study, a key
observation was that this is apparent in multiple tissues as well as
in species other than humans. The present analysis provides a
confirmation of this as a common characteristic of aging, in that
this evident in both brain and lymphocytes. For these two samples
there are also tissue specific themes that have emerged that we
consider a validation of the quality of the expression phenotypes
originally obtained. In the brain sample, consistent with previous
results [11], a decrease in genes involved in synaptic function was
observed, which follows from the documented changes in synaptic
function that occur with age [8]. In lymphocytes, there was
evidence that genes involved in the immune response increase
expression with age, which might be regarded as a reflection of
chronic persisting viruses such as cytomegalovirus (CMV) [17].
While we acknowledge central differences in these samples that
include ethnicity, the age ranges, sample size, and the cell types
represented, in this discussion we highlight these and other
pathways with a comparison of the two different tissues as a
guide.
Table 7. Terms in the Gene Ontology and KEGG pathway databases over-represented among genes that decreased expression
with advancing age in human lymphocytes (1,878 genes in total 13,232).
Category Term P value
a Bonferroni Fold
b Increasing group
c
Fold
b P value
d
GO Bio.Process translation 4.2(10
221) 2.0(10
217) 2.19 0.60 8.7(10
24)
cellular biosynthetic process 6.7(10
221) 3.2(10
217) 1.83 0.79 1.5(10
22)
gene expression 4.0(10
218) 1.9(10
214) 1.36 0.70 3.1(10
211)
ribosome biogenesis and assembly 1.5(10
28) 7.2(10
25) 2.90 0.23 5.9(10
23)
tRNA metabolic process 2.9(10
28) 1.4(10
24) 2.57 0.52 4.7(10
22)
RNA metabolic process 2.2(10
27) 1.0(10
23) 1.24 0.71 6.9(10
29)
RNA processing 8.9(10
27) 4.2(10
23) 1.61 0.23 2.5(10
211)
tRNA processing 4.3(10
26) 2.0(10
22) 2.82 0.63 2.2(10
21)
rRNA processing 8.4(10
26) 3.9(10
22) 2.80 0.16 1.1(10
22)
GO Cell.Component ribosome 2.0(10
223) 1.5(10
220) 3.02 0.09 1.1(10
28)
ribosomal subunit 4.2(10
221) 3.3(10
218) 3.59 0.08 1.1(10
25)
ribonucleoprotein complex 1.6(10
220) 1.3(10
217) 2.19 0.22 3.5(10
212)
organelle lumen 9.0(10
216) 7.0(10
213) 1.71 0.55 2.2(10
27)
mitochondrion 5.0(10
212) 3.9(10
29) 1.62 0.60 7.4(10
26)
small ribosomal subunit 2.7(10
211) 2.2(10
28) 3.72 0.00 1.1(10
23)
large ribosomal subunit 1.4(10
210) 1.1(10
27) 3.45 0.14 4.6(10
23)
cytosolic part 3.1(10
210) 2.5(10
27) 2.60 0.63 8.0(10
22)
nucleolus 5.6(10
210) 4.4(10
27) 2.42 0.47 8.7(10
23)
intracellular organelle part 4.9(10
29) 3.8(10
26) 1.24 0.83 1.4(10
24)
mitochondrial part 6.4(10
29) 5.0(10
26) 1.72 0.63 1.9(10
23)
mitochondrial matrix 1.5(10
28) 1.2(10
25) 2.25 0.39 1.8(10
23)
mitochondrial small ribosomal subunit 4.5(10
25) 3.4(10
22) 4.25 0.00 1.1(10
21)
GO Mol.Function structural constituent of ribosome 9.4(10
222) 2.4(10
218) 3.08 0.10 1.2(10
27)
nucleic acid binding 2.4(10
219) 6.0(10
216) 1.40 0.64 1.1(10
214)
RNA binding 2.6(10
219) 6.7(10
216) 1.95 0.34 1.3(10
211)
methyltransferase activity 3.0(10
26) 7.6(10
23) 2.11 0.33 1.3(10
23)
oxidoreductase activity (NAD or NADP) 5.2(10
26) 1.3(10
22) 2.60 0.76 3.1(10
21)
KEGG Pathway Ribosome 1.1(10
217) 2.2(10
215) 3.97 0.00 3.4(10
25)
aEASE-score, P-value of a modified Fisher’s exact test for overrepresentation [35].
bFold enrichment in each gene group compared to the base set.
cGene group with
expression that increases with advancing age (same genes used in Table 8, 1430 genes).
dHypergeometric test for underrepresentation using annotated genes from a
total set of 13,232 genes as a base population [36].
doi:10.1371/journal.pone.0003024.t007
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specific focus on genes of the mitochondrial respiratory chain [6].
While many of these are included in our emergent lists of genes of
the mitochondrion (see Tables S1 and S3), results indicate that the
effects of age on mitochondrial function may be broader. For
example, in the brain the most significant finding across all
pathways was for cytoplasm genes (Table 3). Although this
categorization includes all genes of the mitochondrion, and indeed
our results suggest it is the latter grouping that contributes to the
strength of the statistic, there remain additional genes that may be
Table 8. Terms in the Gene Ontology and KEGG pathway databases over-represented among genes that increased expression
with advancing age in human lymphocytes (1,430 genes in total 13,232).
Category Term P value
a Bonferroni Fold
b Decreasing group
d
Fold
b P value
e
GO Bio.Process signal transduction 2.1(10
210) 1.0(10
26) 1.34 0.72 8.8(10
211)
immune response 9.2(10
210) 4.3(10
26) 1.84 1.02 6.0(10
21)
defense response 7.0(10
29) 3.3(10
25) 1.90 0.76 2.7(10
22)
response to external stimulus 1.3(10
28) 6.2(10
25) 1.84 0.66 1.4(10
23)
cytoskeleton organization and biogenesis 6.8(10
27) 3.2(10
23) 1.78 0.58 2.4(10
24)
positive regulation of cellular process 9.6(10
27) 4.5(10
23) 1.51 0.97 4.1(10
21)
response to wounding 7.2(10
26) 3.3(10
22) 1.80 0.62 3.0(10
23)
cell adhesion 7.6(10
26) 3.5(10
22) 1.64 0.71 6.0(10
23)
GO Cel.Component plasma membrane 7.0(10
211) 5.5(10
28) 1.42 0.62 1.0(10
213)
membrane part 1.1(10
27) 8.9(10
25) 1.21 0.79 3.5(10
210)
cytoskeleton 1.4(10
27) 1.1(10
24) 1.56 0.69 1.5(10
24)
integral to plasma membrane 2.3(10
26) 1.8(10
23) 1.49 0.69 1.0(10
24)
GO Mol.Function protein binding 9.6(10
210) 2.4(10
26) 1.16 0.93 3.3(10
23)
actin binding 9.1(10
27) 2.3(10
23) 2.07 0.57 4.4(10
23)
signal transducer activity 1.3(10
26) 3.2(10
23) 1.37 0.79 4.8(10
24)
GTPase activity 1.4(10
26) 3.5(10
23) 2.24 0.62 2.7(10
22)
receptor binding 1.5(10
26) 3.7(10
23) 1.68 0.76 1.8(10
22)
GTP binding 1.5(10
25) 3.9(10
22) 1.79 0.86 2.0(10
21)
KEGG Pathway Regulation of actin cytoskeleton 3.1(10
29) 6.0(10
27) 2.44 0.52 6.4(10
23)
Natural killer cell mediated cytotoxicity 1.3(10
25) 2.6(10
23) 2.25 0.26 2.3(10
24)
Focal adhesion 3.2(10
25) 6.4(10
23) 2.02 0.55 1.2(10
22)
aEASE-score, P-value of a modified Fisher’s exact test for overrepresentation [35].
bFold enrichment in each gene group compared to the base set.
cGene group with
expression that decreases with advancing age (same genes used in Table 7, 1878 genes).
eHypergeometric test for underrepresentation using annotated genes from a
total set of 13,232 genes as a base population [36].
doi:10.1371/journal.pone.0003024.t008
Table 9. Genomic architecture comparisons for age associated genes in human brain samples.
Negative asso.
a Positive asso.
b Unregulated P-value
(n=1,369) (n=1,746) (n=9,405)
pre-mRNA length 7565264560 5368362018 6234461186 1.9(10
21)
Coding sequence length 1311628 2057644 1722618 7.0(10
260)
Number of exons 9.260.2 13.060.3 11.260.1 1.1(10
222)
Total intron length 7466264636 5123762033 6062261202 1.4(10
21)
59 UTR length 215662 2 7 662 1 0 62 3.0(10
22)
39 UTR length 1155634 1219629 1202613 3.6(10
21)
Average intron of ea. transcript 86516485 53126249 66486144 1.5(10
29)
Average exon of ea. transcript 424614 435613 42965 9.9(10
21)
Average intron / average exon 28.761.5 16.460.7 21.960.5 5.7(10
210)
All data are base pair 6SEM. P-values were calculated from log10 transformed data using ANOVA.
aNegatively associated genes were those whose expression decreases
with age-at-death (P,0.05).
bPositively associated genes were those for which expression increased with age-at-death (P,0.05). Unregulated genes were those not
significantly correlated with age.
doi:10.1371/journal.pone.0003024.t009
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did emerge as a highly significant term associated with aging in the
brain sample, but not in lymphocytes, indicating that there are
likely to be tissue specific differences in the component genes
related to mitochondrial function (Tables 3 and 7). Nonetheless,
these data together with previous studies provide an intriguing
foundation to investigate if this is a primary event in the aging
process or derivative of a general decrease in energy metabolism
and activity that accompanies old age (e.g. [18]).
That transcript levels are both decreasing and increasing is an
important indication that the aging process does not lead to a
unidirectional decline in expression. While this was evident in both
brain and lymphocytes, in each case the relative fold-enrichment
of gene categories was higher among negatively correlated
transcripts. Thus, the up-regulated categories consisted of more
unique transcripts in general than those that were down-regulated.
In brain we noted several pathways that appear to have
component genes that increase in expression with advancing
age, the foremost among these encompassing genes that encode
nuclear proteins. The most significant categorizations that
emerged included a large contingent of genes related to DNA-
binding and transcription, the most abundant being zinc-finger
proteins. Although genes related to transcription were highlighted
previously, results suggested a mix of both positive and negative
regulation [11]. In contrast however, Miller et al. did observe an
overlap of genes related to transcription that were increasing in
relation to both ageing and to Alzheimer’s disease (AD) [16].
In lymphocytes, immune response was the most significant
category associated with increasing expression. However, there are
several issues that are impossible to resolve for this latter result,
especially regarding which cell types are represented in this sample
(e.g. [19]). For example, this might relate to an accumulation of
highly differentiated T cells due to acceleration by persistent CMV
infection but this would require extensive further study [17]. There
were also some interesting highlights among the many individual
genes that were up-regulated with age in lymphocytes. In
particular the most significant up-regulated gene IGFBP3 is
intriguing in the context that another member of the insulin-like
growth factor binding protein family, IGFBP7 has recently been
implicated as an inducer of apoptosis in human melanoma cell
lines [20,21]. IGFBP3 itself has also been shown to be increased in
senescent human fibroblasts [22]. Those findings together with
results of the present study provide support for the role of insulin-
like growth factor signaling in cellular senescence.
For the brain sample, we were intrigued by the emergent
pattern that expression of cytoplasm genes may be decreasing with
age, while expression of nuclear genes may be increasing with age.
While this might reflect the large number of mitochondrial and
transcription genes in these particular sets, we cannot ignore the
possibility that a basic change in cell morphology might be at play.
One explanation may be that neuronal number remains stable
with age, but synaptic vesicle density decreases [7,8]. This relative
change might give rise to our observations here. In support of this,
genes related to neuronal projections (which includes dendrite
genes) and synapse genes are major categories that appear to
decrease with age (see Table 3). Also in support of this, the highest
ranking individual gene, SVOP, encoding the SV2 related protein,
is localized to the synaptic vesicle and appears to be an ion
transporter. We had anticipated that more neuronal specific genes
would exhibit a decreasing pattern, but noted that even some
common neuronal reference genes, such as ENO2 (ranking
7597
th), were not associated with age. Thus, in contrast to the
enrichment of neuronal projection genes mentioned above (and
see Table 3), this might support the concept that a decrease in
neuronal number is not a major feature of aging [23]. A
potentially important source of confounding in analyses of post-
mortem brain samples is the mode of death, which we have not
examined in more detail in this study. In particular, agonal state
and pH have been highlighted as contributors to brain mRNA
expression [24–26]. The present study has strong similarities with
the study by Li et al., (2004)[25]. However, the relationship
between pH and age was previously explored, but there was no
evidence of a significant correlation [24,27]. Interestingly,
although it was a small sample Vawter et al. also noted significant
correlations of age with mitochondrial genes regardless of agonal
state (see specifically supplementary table 4 from [24]). Nonethe-
less, one explanation might be that transcription factor activation
and mitochondrial deactivation is a natural response to hypoxic
stress which may be more common in elderly individuals (e.g.
[25,28]). Another possibility might be that both aging and
extended hypoxia dependent on the mode of death share
similarities in terms of gene regulation.
For the lymphocyte sample, the most significantly enriched
terms were found in the class of negatively regulated genes, where
Table 10. Genomic architecture comparisons for age associated genes in human lymphocyte samples.
Negative asso.
a Positive asso.
b Unregulated P-value
(n=2,364) (n=1,980) (n=7,898)
pre-mRNA length 5190861755 4948961880 5487961115 1.2(10
26)
Coding sequence length 1724652 1628651 1710618 6.9(10
23)
Number of exons 11.560.2 10.760.2 11.160.1 2.1(10
25)
Total intron length 4970561764 4754961893 5336461135 7.5(10
29)
59 UTR length 195642 1 1 652 0 8 62 1.0(10
23)
39 UTR length 1104625 1134628 1185615 3.9(10
24)
Average intron of ea. transcript 54976209 54636256 56516110 1.5(10
26)
Average exon of ea. transcript 381610 420611 43566 7.7(10
211)
Average intron / average exon 20.561.0 17.760.7 19.260.4 7.1(10
210)
All data are base pair 6SEM. P-values were calculated from log10 transformed data using ANOVA.
aNegatively associated genes were those whose expression decreases
with age (P,0.05).
bPositively associated genes were those for which expression increased with age (P,0.05). Unregulated genes were those not significantly correlated
with age.
doi:10.1371/journal.pone.0003024.t010
Transcriptome Senescence
PLoS ONE | www.plosone.org 10 August 2008 | Volume 3 | Issue 8 | e3024the ribosomal and translation machinery appears to be strongly
affected by age. This could potentially contribute to ‘‘immuno-
senescence’’, whereby the immune system decays with time,
rendering elderly individuals more susceptible to infectious
diseases [29]. While changes at the expression level for this class
of genes have to our knowledge not been previously reported on
this scale, the concept that protein synthesis is involved in
immunosenescence is not new [30]. This result is in our view the
most striking difference between lymphocytes and brain.
Although this suggests a more general decreases in metabolism
in aging lymphocytes, we consider this an important reminder
that tissue specificity can play a major role in gene expression
profiling [31].
Another important feature of this study is the relative degree of
stability in gene expression across the age spectrum. To put this in
context, the strongest effects of age on any genes were 18%
variance explained for TAC3 in brain and 29% for LRRN3 in
lymphocytes, but in examining Tables 1, 2, 5 and 6, it is apparent
that effect sizes drop off rapidly. For each of these top-ranked
genes there was an approximately 2-fold change in average
expression levels over the age ranges. This is comparable to well
documented changes in hormone levels with age, such as for IGF1
[2,32]. Also of note, genes claimed to be changing with age
previously exhibited differences between young and older groups
in the range of 2–3 fold [11]. This again might suggest that cell-
loss and/or changes in organ function/morphology are more
important than broad changes in gene expression in the decrease
in health that typically accompanies increasing age. The possibility
however cannot be excluded that relatively small changes in gene
expression have a large impact on cell function. As an example,
disorders such as Parkinson’s disease (PD) can be caused by simple
gene dosage effects, as has now been shown for the SNCA gene
which encodes alpha-synuclein [33]. Although rare, we noted
several genes that may be changing to a larger degree, but which
fell below a strict significance threshold, for example ZIC3 in
brain. However, there were no similar cases in the much more
powerful lymphocyte sample.
Finally, we also explored basic gene architecture characteristics
in an attempt to provide some insight into why expression might
vary with age. The only parameter that emerged as significant and
equivalent in both brain and lymphocytes was the intron/exon
length ratio, this representing a metric of gene ‘‘compactness’’
[13]. This might be interpreted as suggesting that non-compact
genes are more susceptible to mutations that disrupt regulation,
and thus lead to decreasing expression with advancing age.
However, we cannot exclude the possibility that what we are
seeing is simply a result of the gene pathways that are over-
represented, these being enriched for compact or non-compact
genes. In other words, if specific pathways are affected by age, the
genes that represent those pathways may have similar features. We
consider this nonetheless an intriguing finding in that it is
replicating in different tissues.
In summary, we validate previous findings that a decrease in
mitochondrial gene expression appears to be a common theme in
the aging process. Whether this is a primary event that causes a
decline in health with advancing age or a result of a general
decrease in metabolism in the elderly remains a topic for further
investigation. We also highlight additional novel pathways that
may be age dependent but with dramatic differences between
tissues, in particular with genes related to transcription and to
translation. These results may provide a valuable foundation for
understanding the molecular consequences of aging and empha-
size the development of catalogues of senescence-related genes in
additional tissues.
Materials and Methods
Human Samples
The primary sample used in this study consisted of 191
individuals with ages-at-death data ranging from 65–100 years for
which brain autopsy tissue was obtained. Expression level data
were obtained using the Illumina HumanRefSeq-8 expression
BeadChip platform for a total of 14,078 transcripts in which
expression was detected in 5 or more individuals. Detailed
descriptions of the human samples as well as the expression
profiling protocol are provided in the original publication for
which this sample was presented [12]. To create a working dataset,
expression phenotypes and covariate data were merged that
included age-at-death, post-mortem interval (pmi), gender, brain
region, and transcript detection rates. From this, we generated 2
additional covariates for 1) total average expression level from all
transcripts and 2) total average expression level for all transcripts
that were detected in all individuals (5269 transcripts fulfilled the
latter criteria). All individual transcript levels, the global average
transcript levels, and pmi were log10 transformed prior to inclusion
in analyses.
The second sample consisted of 1240 individuals ranging in age
from 15-94 in which fresh blood lymphocytes had been obtained
and mRNA extracted. Expression phenotyping was conducted
using the Illumina Sentrix Human Whole Genome (WG-6) Series
I BeadChip platform. In total there were 19,648 individual
transcript measures, representing approximately 18,500 genes.
Details of the sample and expression protocols have been provided
previously in the original publication describing this sample [15].
For our analysis, we used the normalized expression phenotypes
without further transformation.
Correlation of Age and Transcript Level
We classified the extremes as outliers that are expected to be
observed once or more in 1930 individual log transformed
transcript estimates with assumption of independence and normal
distribution of 193 measures for each transcript.
a0~1{ 1{a ðÞ
1=k
where a9 is the alpha level for each measure, a is 0.05 and k 193.
Based on normal distribution assumption,
W{1 a0 ðÞ ~z&3:4644
where W is standard normal cumulative distribution fuction, z is z-
score of each measure.
The normality of log transformed observed values for each
transcript was tested by means of a Shapiro-Wilk W test. To assess
differences of transcript detection rates or global expression levels
across brain regions, as well as to test differences in characteristics
of genomic architecture between age-related gene sets, ANOVA
was used. Contingency tables (for example comparing the
proportions of housekeeping genes) were evaluated by means of
a standard chi-square test. All statistical analyses not related to
pathway based tests were performed using STATA se 9.0. For the
brain sample, the dependency of expression level on age-at-death
was tested by fitting a linear regression model for each transcript:
Y~b0zb1x1zb2x2ze:
where Y is the log10 transformed expression level of the transcript,
x1 age-at-death, x2 log10 of global expression, b0 intercept, b1 and
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the lymphocyte sample, the same test was applied but without the
global expression covariate according to the following:
Y~b0zb1x1ze
where Y is the normalized expression level of each transcript, x1
age, b0 intercept, b1 slope of age, and e random error. We also
allowed for non-independence of expression measures given the
relatedness of family members in the lymphocyte sample [34].
Gene Ontology and KEGG Pathway Analyses
The Entrez Gene IDs, symbols, and descriptions of genes for all
tested transcripts were attained by Entrez Programming Utilities
(eUtils) using GI number with the aid of a Perl script. This
facilitated a search for replaced sequence identifiers and extracted
information of interest by scanning the output text files from
Entrez eUtils on the transcripts. Using the attained Entrez Gene
IDs as identifiers of genes, we obtained the total lists of both Gene
Ontology terms and KEGG pathway descriptors, with which our
selected set of genes was annotated and analyzed using the
DAVID functional annotation tool [14] with the most recent data
update (January, 2008). The EASE scores [35] from the DAVID
tool were used in trimming to over-represented term lists, with
Bonferroni corrections of the scores from the tool as an inclusion
criteria of Tables 3, 4, 7 and 8. We scrutinized ancestor-
descendant relationships in the Gene Ontology structure among
the terms in the enrichment lists on the basis of is_a, part_of, and
regulates relationship by scanning the master ontology file which
was updated in April, 2008. Our goal with this was to determine if
ancestor terms had emerged as significant primarily because of
enrichment of one of their descendant terms. We detail our
strategy for this in Figure S1. Among the GO terms in the list,
those which had no descendants were labeled as ‘end-terms’. For
every term excluding end-terms, we created the artificial
descendants. These were intended to represent the complement
of the set of genes annotated with a descendant term in the list with
respect to all genes in the ancestor. The artificial term for every
descendant of every ancestor in the list was then tested to
determine if it was over-represented by applying a hypergeometric
test [36]. The ancestors for which all artificial descendant terms
were over-represented at P,0.005 were labeled ‘significant
ancestor terms’. The terms whose artificial descendants for end-
terms or significant ancestors were over-represented were added to
the set of ‘significant ancestor terms’. After modifying the set, the
terms in the set were checked if they fulfilled inclusion criteria
(enriched complement at P,0.005) and the set was updated
iteratively until there was no change. The end-terms and
significant ancestor terms are listed in Tables S1, S2, S3, S4.
The remaining terms in the enrichment list follow in the same
tables that are significantly over-represented mainly by a highly
enriched descendant. P-values of the enrichment test for the
artificial terms are also shown in the Tables S1, S2, S3, S4.
Genomic Architecture of Age-related Gene Sets
The genomic positions of start and end points of transcripts,
their coding sequences, and their exons and introns in both brain
and lymphocyte gene sets were collected from the UCSC genome
browser using Genbank accession numbers (e.g. NM_018711) as
identifiers. Information on some of the transcripts that were
detected in both samples was not available from the UCSC
browser due to the records being suppressed. Therefore, the
number of transcripts in the genomic architecture analysis was
reduced to 12,520 and 12,242 for brain and lymphocyte samples,
respectively. Based on the positional data, lengths of pre-mRNA
sequences, coding sequence, total intron, 59UTR, 39UTR, average
intron and average exon of each transcript, as well as the number
of exons and the ratio of intron per coding sequence length were
calculated and transformed on a log10 scale. For comparative
analyses of gene characteristics, the transcripts were divided into 3
groups, up-regulated genes (positively correlated with age at a
P,0.05 threshold), down-regulated (negatively correlated with age
at a P,0.05 threshold), and a set of genes that were not
significantly altered over the age spectrum. Differences between
groups were assessed using ANOVA. Combined analyses were
performed on both sets using second order factorial ANOVA with
sample source as a covariate.
URLs
Entrez Gene: http://www.ncbi.nlm.nih.gov/sites/entrez?db=
gene; Entrez eUtils: http://eutils.ncbi.nlm.nih.gov/entrez/eutils;
DAVID 2008: http://david.abcc.ncifcrf.gov/; Gene Ontology
(GO): http://www.geneontology.org/; UCSC genome browser:
http://genome.ucsc.edu/
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Found at: doi:10.1371/journal.pone.0003024.s001 (0.06 MB
PDF)
Table S1 Terms in the Gene Ontology and KEGG pathway
databases enriched among genes that decreased expression with
advancing age in brain (1450 genes in total 13,216)
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PDF)
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Table S3 Terms in the Gene Ontology and KEGG pathway
databases enriched among genes that decreased expression with
advancing age in the human lymphocytes (1878 genes in total
13,232)
Found at: doi:10.1371/journal.pone.0003024.s004 (0.13 MB
PDF)
Table S4 Terms in the Gene Ontology and KEGG pathway
databases enriched among genes that increased expression with
advancing age in the human lymphocytes (1430 genes in total
13,232)
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